Alzheimer's research turns to the gut, blood vessels and brain plumbing
At Neuroscience 2026, scientists reported leaky gut in long COVID patients, slower waste clearance in healthy older adults and plastic-like particles in deep brain vessels.
By Letizia Giugliano
3 min read

New evidence presented at Neuroscience 2026 links Alzheimer's disease to the gut, to blood vessels deep in the brain and to the organ's own waste-clearance channels. The findings were released in a summary on 14 November 2026 and come from studies of long COVID patients, healthy older adults and rats bred to model early disease. The summary describes no patent filing, no intellectual property licence and no medical device approval: the work sits at the research stage.
Four findings on the gut, the vessels and the glymphatic system
Alzheimer's disease has been studied for more than a century and remains incurable. It affects more than 7 million Americans, according to the Alzheimer's Association, and 35 to 40 million people worldwide, according to the World Health Organization, as reported in the Society for Neuroscience summary of its annual meeting.
The four results presented at Neuroscience 2026 point in different directions. Long COVID patients showed gut symptoms tied to higher amyloid in the blood. Healthy older adults cleared waste from the brain less efficiently. People who died with Alzheimer's had plastic-like particles near blood vessels in deep brain tissue. And rats given probiotic and prebiotic supplements did not develop early memory deficits.
Photo: engin akyurt / Unsplash
Each finding concerns a different body system, which is the point the session's moderator made.
“Many different systems of the body can contribute to Alzheimer's disease.”
— Maiken Nedergaard, co-director of the Center for Translational Neuromedicine, University of Rochester Medical Center
Leaky gut, amyloid and a rat that kept its memory
In patients with long COVID, researchers found what the summary calls "leaky gut" symptoms, and those symptoms were related to higher amyloid levels in the blood. Amyloid is the protein fragment that clumps into plaques in the brains of people with Alzheimer's; finding it in blood, and linking it to a gut condition, adds evidence that the gut microbiome plays a part in raising the risk of the disease, according to the meeting summary.
The animal work goes further. In a rat model of preclinical Alzheimer's, animals given probiotic and prebiotic supplements did not develop the early learning and memory deficits expected at that stage, which suggests that changing gut bacteria can influence how the disease starts. The summary reports the result without giving the doses, the duration of supplementation or the size of the groups.
The brain's plumbing slows down with age
The glymphatic system, the network that flushes fluid through brain tissue and carries waste away, was discovered by Maiken Nedergaard and her team in 2012. Nedergaard is co-director of the Center for Translational Neuromedicine at the University of Rochester Medical Center and a professor at the University of Copenhagen, and she moderated the press conference.
At the meeting, researchers reported that older adults, including those in good health, had less efficient brain waste-clearance systems, and that the slowdown was associated with lower cognitive function. The finding puts age-related changes in fluid movement alongside the protein clumps usually treated as the disease's signature.
Plastic-like particles in deep brain vessels
Tissue from patients who died of Alzheimer's contained plastic-like particles in or around blood vessels in deep brain tissue. The summary states that these particles may raise the risk of blood vessel haemorrhage or inflammation. It does not say what the particles are made of, how they got there or how many patients were examined, and the authors present the link as a possible risk rather than a demonstrated cause.
Nedergaard framed the range of results in broad terms. "Many different systems of the body can contribute to Alzheimer's disease," she said, according to the Society for Neuroscience.
No patent numbers, no filings, no device approvals in the record
Conference abstracts rarely carry the paperwork of a patent application, and this set is no exception. The summary published on 14 November 2026 names no inventor, no assignee, no filing date and no granted patent on gut-based risk markers, glymphatic imaging or the probiotic formulation tested in rats.
That is not surprising at this stage. The scientists involved say they are working out the mechanisms that connect body and brain in order to develop and improve treatments, which is the step before any intellectual property claim or medical device submission becomes concrete. What to watch is whether the probiotic result in rats is repeated in people and whether waste-clearance measurement turns into a test that can be used in patients. Neither step appears in the record yet.
AI-assisted article



